Kim Kardashian's Take on 23andMe: The Good, the Bad, and the DNA

Kim's Stock Market Swoon

Hey dolls! Have you heard the latest tea on 23andMe? Well their stock took a major hit plunging 21% after reporting some not so great third quarter fiscal results. Yikes! Looks like they need some good vibes from the Kardashian clan.

The Numbers Don't Lie

According to reports 23andMe's revenue for the quarter was $45 million down from $67 million last year. And get this their net loss for the quarter was a whopping $278 million! I guess even I can't keep up with those kind of losses.

To Split or Not to Split

During their investor call 23andMe's CEO Anne Wojcicki mentioned the possibility of splitting up their consumer and therapeutics businesses. Honey they're trying to expand their investor base but I can't help but wonder if they're just taking some advice from my famous split with Kris Humphries.

The Rise and Fall of 23andMe

Once upon a time 23andMe was the belle of the ball. Their at home DNA testing kits were all the rage giving people insights into their ancestry and genetic profiles. They even went public and became a CNBC Disruptor 50 company. But now their share price has tumbled more than 95% from its peak. Talk about a fall from grace!

Legal Troubles and Data Breaches

It seems like 23andMe just can't catch a break. Not only are they dealing with declining revenue and a potential split but they're also facing over 30 class action lawsuits following a major data breach. Honey they're in deeper legal trouble than when I accidentally uploaded that selfie with my bathroom sink.

Analysts Aren't Impressed

Those analysts at Citi aren't mincing their words. They're cautious about 23andMe's outlook especially with all the legal issues and reputational risks. They even lowered their target price for the stock. Ouch! Looks like 23andMe needs a Kardashian level makeover to turn things around.